Open Access Case Report Article ID: AHCRR-3-112

    Spontaneous Subcapsular Hematoma from Rivaroxaban

    Swetha Chenna, Amy R Hurst, Jason B Douglas, Venu Madhav Chippa*, Matthew R Fulton and Amr Moussa

    Rivaroxaban was approved for stroke prevention for non-valvular atrial fibrillation in 2011, with added advantage of decreased risk of bleeding in comparison to coumadin, made it a good alternative for coumadin. We report a case of severe subcapsular and intrarenal hematoma associated with Rivaroxaban in an elderly male with chronic kidney disease. He presented with severe left sided flank pain, shock and acute on chronic renal failure, he was successfully resuscitated with supportive care. We aim to alert primary care physicians, hospitalists, Emergency room physicians and cardiologists regarding the likelihood of encountering similar cases as the indications of direct acting oral anticoagulants are increasing and gaining more popularity in physicians and patients as well.

    Keywords: Rivaroxaban; Renal hematoma; Shock

    Published on: Dec 21, 2018 Pages: 4-6

    Full Text PDF Full Text HTML DOI: 10.17352/ahcrr.000012
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Pinterest on AHCRR